David Addis’s latest position was Counsel at Schuyler, Roche & Crisham (previousely Schuyler, Roche & Zwirner). The firm recently closed. David Addis’s practice encompassed US foreign trade controls, including export controls, technology controls and encryption regulation, and antitrust counseling on mergers and acquisitions, joint ventures and other competitor collaborations, and intellectual property licensing, including IP licensing policies for standard-setting organizations. Mr. Addis has extensive experience with US foreign trade controls, export regulations and embargo sanctions administered by the Departments of Commerce, Treasury, State and Homeland Security, and advises on compliance, obtaining licensing, and responding to possible enforcement actions.
63
On November 6, the Federal Trade Commission (“FTC”) amended the implementation rules of the Hart Scott Rodino Antitrust Improvements Act (the “HSR Act”) to specify when parties to pharmaceutical patent license agreements must observe the HSR Act’s notification and pre-closing waiting period (...)
64
On July 7, 2011, the Federal Trade Commission and the Department of Justice (“the Agencies”) announced significant changes to the form and accompanying materials that companies must submit when reporting transactions under the Hart-Scott-Rodino Antitrust Improvements Act (“HSR Act”). Although (...)
62
The Federal Trade Commission (“FTC”) has announced new monetary thresholds for the Hart-Scott-Rodino (“HSR”) Act effective February 22, 2010. See 75 Fed. Reg. 3468 (Jan. 21, 2010). The new thresholds will be approximately 3% lower than those currently in effect. For example, the minimum (...)
86
On April 22nd, the DC Circuit Court of Appeals set aside the FTC’s 2006 decision that Rambus Inc. unlawfully monopolized four technology markets through deceptive conduct during the JEDEC standards development process for two widely-implemented computer memory standards. The Court held that (...)
55
On October 30, 2006 the Antitrust Division released a new business review letter http://www.usdoj.gov/atr/public/busreview/219380.htm that looks favorably on a standards development organization’s (SDO) proposed patent policy that requires participants to predisclose the maximum royalty rates (...)
50
On April 4, 2006, the FTC published notice of its intention to conduct an extensive study of the economic effects of authorized generic pharmaceuticals. See 71 Fed. Reg. 16,779 (April 4, 2006). The initial stage of the study would involve detailed information requests, akin to subpoenas, to as (...)
